Senzime AB (SEZI) AI Stock Analysis

• Market Cap: kr982.59M
• Dividend Yield: N/A
• Average Volume (3M): 379.32K
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: 71.41%
• EPS Growth: 17.26%
• Country: SE
• Employees: 54
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -0.22
• Shares Outstanding: 157,215,040
• 10 Day Avg. Volume: 472,964
• 30 Day Avg. Volume: 379,318
• PEG Ratio: 1.35
• Price to Book (P/B): 2.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr4.97
• Price Target Upside: -15.02% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: kr5.50 ▼(-5.98%Downside)

The overall stock score reflects strong revenue growth and a positive technical outlook, which are counterbalanced by ongoing financial losses and a challenging valuation. Without earnings call insights or corporate events, the score primarily hinges on financial performance and technical analysis.

Senzime AB Business Overview & Revenue Model

Company Description

Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.

How the Company Makes Money

Senzime AB generates revenue primarily through the sale of its medical monitoring systems to hospitals and healthcare providers. The company's revenue model is based on the direct sales of its products, as well as recurring revenue from disposable sensors used with their monitoring devices. Key revenue streams include the TetraGraph system, which is widely used for neuromuscular monitoring during surgery. Senzime also benefits from strategic partnerships and collaborations with healthcare institutions and distributors to expand its market reach.

Senzime AB Financial Statement Overview

Summary

Senzime AB displays significant revenue growth and a strong equity position, with an equity ratio of 80.62%. However, it remains unprofitable with negative net profit and free cash flow margins, indicating challenges in achieving profitability and sustainable cash generation.

Income Statement

Senzime AB shows significant revenue growth with a 95.63% increase from 2022 to 2023 and a 19.44% increase in TTM. However, the company remains unprofitable with a negative net profit margin of -179.56% in TTM. The gross profit margin improved to 38.72% in TTM but is offset by high operating losses, as indicated by negative EBIT and EBITDA margins.

Balance Sheet

The company's balance sheet reflects a strong equity position with an equity ratio of 80.62% in TTM, indicating financial stability. However, the debt-to-equity ratio is low at 0.07, and the return on equity is negative due to ongoing losses. The company has a solid cash position with negative net debt, highlighting its ability to meet short-term obligations.

Cash Flow

Senzime AB exhibits negative free cash flow, though the operating cash flow to net income ratio is 0.87, suggesting cash expenses closely track net income losses. There is no free cash flow growth, as it remains negative in TTM, emphasizing the need for the company to improve operational efficiency to generate positive cash flows.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	58.48M	35.75M	14.03M	10.98M	9.34M
Gross Profit	20.12M	8.34M	-4.39M	-4.92M	-7.90M
EBITDA	-95.53M	-118.82M	-120.05M	-73.20M	-36.96M
Net Income	-118.73M	-134.15M	-132.70M	-82.14M	-47.45M
Balance Sheet
Total Assets	424.53M	433.54M	322.68M	174.62M	258.89M
Cash, Cash Equivalents and Short-Term Investments	100.94M	151.01M	26.04M	74.87M	160.31M
Total Debt	22.67M	11.47M	13.04M	1.63M	2.40M
Total Liabilities	78.67M	58.06M	60.78M	24.04M	27.55M
Stockholders Equity	345.86M	375.48M	261.90M	150.58M	231.35M
Cash Flow
Free Cash Flow	-126.28M	-121.73M	-141.89M	-84.30M	-38.66M
Operating Cash Flow	-105.94M	-113.91M	-136.78M	-81.33M	-38.34M
Investing Cash Flow	-20.34M	-7.82M	-4.98M	-2.97M	-327.00K
Financing Cash Flow	75.86M	246.51M	92.36M	-945.00K	167.69M

Senzime AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEZI, the sentiment is Positive. The current price of 5.85 is above the 20-day moving average (MA) of 5.40, above the 50-day MA of 5.16, and above the 200-day MA of 5.53, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 68.48 is Neutral, neither overbought nor oversold. The STOCH value of 70.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SEZI.

Senzime AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	kr1.16B	45.15	7.87%	―	-10.34%	-59.69%
Sector *	63 Neutral	S$1.62B	4.13	2.87%	2.62%	17.84%	20.03%
MAGLE	60 Neutral	kr529.31M	32.26	2.10%	―	64.21%	-29.10%
SEZI	54 Neutral	kr982.59M	―	-35.36%	―	71.41%	17.26%
SEDANA	53 Neutral	€1.33B	―	-5.40%	―	16.27%	-22.61%
XSPRAY	47 Neutral	kr1.91B	―	-42.24%	―	―	-19.44%
VICO	45 Neutral	€1.83B	―	-40.15%	―	―	63.85%

Senzime AB Corporate Events

Senzime Completes MSEK 110 Share Issue with Full Subscription

Senzime AB has successfully completed the full subscription of its directed share issue, raising MSEK 110 through the issuance of 24,000,000 shares. This capital increase will support the company’s growth, resulting in a 15.27% dilution of shares, and reflects strong investor confidence in Senzime’s market position and future prospects.

Senzime’s Licensee Secures US and UK Approvals for HN-100 Module

Senzime AB announced that its licensee, Fukuda Denshi, has obtained FDA and UKCA approvals to introduce the HN-100 neuromuscular transmission module in the US and UK. This development is significant for Senzime as it expands Fukuda’s market reach, leveraging Senzime’s TetraGraph® technology, and potentially increasing revenue through manufacturing and royalty agreements.

Senzime AB Announces Q2 2025 Financial Report Presentation

Senzime AB has announced a webcast presentation of its second quarter 2025 financial report, scheduled for July 18. The presentation, led by CEO Philip Siberg, will provide insights into the company’s performance and will include a Q&A session, reflecting Senzime’s commitment to transparency and engagement with investors and stakeholders.

Senzime Secures Major U.S. Hospital Contract for TetraGraph Monitors

Senzime AB has secured a significant contract with a major U.S. university hospital system to supply its TetraGraph monitors and engage in scientific collaboration. This agreement, which involves the installation of 63 monitors in Texas, aims to standardize neuromuscular monitoring for over 27,000 patients annually. The collaboration will leverage Senzime’s TetraConnect platform and AI analysis to enhance anesthesia care through personalized, data-driven approaches. This milestone not only represents one of Senzime’s largest installations but also sets a benchmark for implementing Quality Improvement initiatives in anesthesiology, potentially transforming patient monitoring and management during surgery.

Senzime Secures New U.S. Patent for TetraGraph System

Senzime AB has been granted a new U.S. patent for its TetraGraph system, which enhances the system’s capabilities by improving the quality of electromyography signals. This patent strengthens Senzime’s competitive position in the neuromuscular monitoring field, highlighting their commitment to innovation and patient safety.

Senzime AB Approves Directed Share Issue to Adam Dahlberg

Senzime AB held an extraordinary general meeting where shareholders unanimously approved a directed share issue, allowing Adam Dahlberg to subscribe for up to 700,000 new shares at SEK 4.60 each. This decision will increase the company’s share capital by a maximum of SEK 87,500, potentially impacting its financial structure and market positioning.

Senzime Completes First Tranche of Directed Share Issue

Senzime AB has completed the first tranche of its directed share issue, successfully allocating 22,250,000 out of 23,300,000 shares, resulting in a capital increase of approximately MSEK 102.38. This move, involving new and long-term institutional investors, aims to bolster the company’s financial standing and expand its shareholder base, with the second tranche pending approval at an extraordinary general meeting.

Senzime AB Calls Extraordinary Meeting for Share Issue Approval

Senzime AB has announced an extraordinary general meeting to be held on June 30, 2025, to approve a directed share issue. This strategic move aims to inject new capital into the company by issuing a maximum of 700,000 new shares, specifically directed to Adam Dahlberg, to strengthen its financial position and support its growth initiatives.

Senzime AB Announces SEK 110 Million Directed Share Issue to Fuel Expansion

Senzime AB has announced a directed share issue to raise SEK 110 million, aimed at supporting its commercial expansion, innovation projects, and working capital needs. The share issue involves new and existing investors, including significant institutional investors, and is intended to strengthen the company’s shareholder base, providing increased security and stability. The decision to opt for a share issue over loan financing reflects the company’s strategic focus on cost efficiency and investor support.

Senzime Applauds New European Pediatric Guidelines for Neuromuscular Monitoring

Senzime AB welcomes the pre-announcement of new European pediatric guidelines for quantitative neuromuscular monitoring during anesthesia, revealed at the Euroanaesthesia 2025 congress. This development is significant for pediatric anesthesia, as it recommends EMG-based monitoring technology, aligning with Senzime’s TetraGraph system, which is FDA-cleared for use on patients as young as one month. The guidelines represent a substantial market opportunity for Senzime, addressing the historical lack of specialized pediatric solutions and aiming to reduce the risks of residual neuromuscular block in pediatric surgeries.

Senzime AB Announces Key Resolutions from Annual General Meeting

Senzime AB’s annual general meeting resulted in several key resolutions, including the adoption of the 2024 financial statements, re-election of board members, and the introduction of a new employee stock option program. These decisions aim to strengthen the company’s governance and incentivize its workforce, potentially enhancing its market position and operational effectiveness.